 |
 |
|
|
RESÚMENES NOVIEMBRE 2008 |
Schizophrenia-Psychotic Disorders & Antipsychotics
(Haga un click en la
información del journal para acceder al resúmen)
5 – doble-ciego o
metanálisis; 4 – subanálisis o simple ciego; 3 –
revisión, abierto, básico; 2 – casos; 1 – opinión
GRATIS = Texto gratuito en algunos países de la región iberoamericana
(algunos artículos requieren ir a la tabla de contenidos del
número actual de la revista)
3 - Effects
of cannabis use on outcomes of psychotic disorders: systematic review
Stanley Zammit,
Theresa H. M. Moore, Anne Lingford-Hughes, Thomas R.
E. Barnes, Peter B. Jones, Margaret Burke, Glyn Lewis
The British Journal of Psychiatry (2008) 193:
357-363
3< - Aripiprazole: 6-month outcomes in a retrospective
naturalistic study
Paul N. Deslandes; Arwel Thomas; Eve E. Blackmore; Robert D. E.
Sewell
International
Journal of Psychiatry in Clinical Practice, Volume 12,
Issue 4 2008, pages 243 - 246
3< - An open
multicentre pilot study examining the safety, efficacy and tolerability of fast
titrated (800 mg/day by day 4) quetiapine in the
treatment of schizophrenia/schizoaffective disorder
J. Peuskens; J. M. Devoitille;
J. Kusters; G. Vandenhoven
International
Journal of Psychiatry in Clinical Practice, Volume 12, Issue 4 2008 , pages 261 - 267
5 -
Metabolic effects of olanzapine and risperidone in patients with psychotic disorders
Mitra Safa; Saeed
Sadr; Bahram Delfan; Mandana Saki;
Mohammad Javad Tarrahi
International
Journal of Psychiatry in Clinical Practice, Volume 12,
Issue 4 2008, pages 299 - 302
3! - Familial
Predisposition for Psychiatric Disorder. Comparison of Subjects Treated for
Cannabis-Induced Psychosis and Schizophrenia
Mikkel Arendt, Preben
B. Mortensen, Raben Rosenberg, Carsten
B. Pedersen, Berit L. Waltoft
Arch Gen Psychiatry. 2008;65(11):1269-1274
3 - Olanzapine: review of safety 2008
Joshua T Kantrowitz & Leslie Citrome
Expert Opinion on Drug Safety. November 2008, Vol. 7, No. 6, Pages 761-769
3 -
Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivopharmacology in rats
Jenny L. Wiley, Seth H. Kendler, James J. Burston, Daniel R. Howard, Dana E. Selley and Laura J. Sim-Selley
Neuropharmacology. Volume 55, Issue 7, December 2008, Pages 1183-1190
3 - Clozapine causes oxidation of proteins involved in energy
metabolism: a possible mechanism for antipsychotic-induced metabolic
alterations
Consuelo Walss-Bass, Susan T. Weintraub, John Hatch, Jim Mintz and Asish R. Chaudhuri
The
International Journal of Neuropsychopharmacology
(2008), 11:1097-1104
GRATIS 3
- New and old
antipsychotics: what ‘effectiveness’ trials tell us
Panayiota G. Michalopoulou, Sukhwinder
S. Shergill and Shitij Kapur
Psychiatry. Volume 7, Issue 11,
November 2008, Pages 443-446
GRATIS 3
- Late-onset
schizophrenia and very late-onset schizophrenia-like psychosis
Niall Boyce and Zuzana
Walker
Psychiatry. Volume 7, Issue 11,
November 2008, Pages 463-466
GRATIS 3!
- Treatment of
first-episode and prodromal signs
Swaran P. Singh and Cristina Merino
Psychiatry.
Volume 7,
Issue 11, November 2008, Pages 467-471
GRATIS 3
- Physical health in
schizophrenia and related disorders
Khalida Ismail
Psychiatry. Volume 7, Issue 11,
November 2008, Pages 472-476
GRATIS 3! - Treatment resistance in schizophrenia
Thomas R.E. Barnes and Serdar Dursun
Psychiatry.
Volume 7, Issue 11, November 2008, Pages 487-490
3! - Sex
differences in schizophrenia and other psychotic disorders: a 20-year
longitudinal study of psychosis and recovery
Linda S. Grossman, Martin
Harrow, Cherise Rosen, Robert Faull and Gregory
P. Strauss
Comprehensive
Psychiatry. Volume 49, Issue 6, November-December 2008, Pages
523-529
3! - Upcoming
Agents for the Treatment of Schizophrenia: Mechanism of Action, Efficacy and
Tolerability
Bishara,
Delia; Taylor, David
Drugs, Volume 68, Number 16, 2008
, pp. 2269-2292(24)
3! - Cumulative social disadvantage,
ethnicity and first-episode psychosis: a case-control study
C. Morgan, J. Kirkbride, G. Hutchinson, T. Craig, K.
Morgan, P. Dazzan, J. Boydell, G. A.
Doody, P. B. Jones, R. M.
Murray, J. Leff and P. Fearon
Psychological
Medicine (2008), 38:1701-1715
5 - A
Double-Blind, Randomized Comparative Study of Aripiprazole
and Olanzapine in Patients with Schizophrenia
W. Wolfgang Fleischhacker,
Robert D. McQuade, Ronald N. Marcus, Donald
Archibald, René Swanink and William H. Carson
Biological Psychiatry. Article in
Press, November
2008
3 - ADX47273
[S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]:
A Novel Metabotropic Glutamate Receptor 5-Selective
Positive Allosteric Modulator with Preclinical
Antipsychotic-Like and Procognitive Activities
Feng
Liu, Steve
Grauer, Cody
Kelley, Rachel Navarra, Radka
Graf, Guoming
Zhang, Peter
J. Atkinson, Michael
Popiolek, Caitlin
Wantuch,Xavier Khawaja, Deborah Smith, Michael Olsen, Evguenia
Kouranova, Margaret Lai, Farhana
Pruthi, Claudine
Pulicicchio, Mark Day, Adam Gilbert,Mark
H. Pausch, Nicholas J. Brandon, Chad E. Beyer, Tom
A. Comery, Sheree
Logue, Sharon
Rosenzweig-Lipson, and Karen
L. Marquis
5 - Olanzapine Versus Aripiprazole for the Treatment of Agitation in Acutely Ill
Patients With Schizophrenia
Kinon, Bruce
J;
Journal of Clinical
Psychopharmacology. 28(6):601-607,
December 2008
3! - A 2-Year Prospective Follow-Up Study of Lower Urinary Tract Symptoms in
Patients Treated With Clozapine
Jeong, Seong Hoon; Kim, Jong Hoon; Ahn,
Yong Min; Lee, Kyu Young; Kim, Soo-Woong;
Jung, Dong Chung; Kim, Yong Sik
Journal of Clinical
Psychopharmacology. 28(6):618-624,
December 2008
3 - Striatal and Extrastriatal
D2/D3-Receptor-Binding Properties of Ziprasidone: A
Positron Emission Tomography Study With [18F]Fallypride and [11C]Raclopride
(D2/D3-Receptor Occupancy of Ziprasidone)
Vernaleken, Ingo;
Fellows, Christine; Janouschek, Hildegard; Brocheler, Anno; Veselinovic, Tanja; Landvogt, Christian; Boy,
Christian; Buchholz, Hans-Georg; Spreckelmeyer, Katja; Bartenstein, Peter;
Cumming, Paul; Hiemke, Christoph;
Rosch, Frank; Schafer, Wolfgang; Wong, Dean F; Grunder, Gerhard
Journal of Clinical
Psychopharmacology. 28(6):608-617,
December 2008
3 - Predictors for Starting Depot Administration of Risperidone
in Chronic Users of Antipsychotics
Vehof, Jelle; Postma, Maarten J; Bruggeman, Richard; De Jong-Van
Den Berg, Lolkje T. W; Van Den Berg, Paul B; Stolk, Ronald P; Burger, Huibert
Journal of Clinical
Psychopharmacology. 28(6):625-630,
December 2008
3! - Antipsychotic-Induced Hyperprolactinemia: A
Cross-Sectional Survey
Johnsen, Erik; Kroken, Rune A; Abaza, Mirsad; Olberg, Henning;
Jorgensen, Hugo A
Journal of Clinical
Psychopharmacology. 28(6):686-690,
December 2008
3 - Influence of Olanzapine on QT Variability and
Complexity Measures of Heart Rate in Patients With
Schizophrenia
Bar, Karl-Jurgen; Koschke, Mandy; Berger,
Journal of Clinical
Psychopharmacology. 28(6):694-698,
December 2008
3 - Dose–Occupancy Study of Striatal and Extrastriatal
Dopamine D2 Receptors
by Aripiprazole in Schizophrenia with PET and [18F]Fallypride
Lawrence S Kegeles, Mark Slifstein, W
Gordon Frankle, Xiaoyan Xu, Elizabeth Hackett, Sung-A Bae,
Robyn Gonzales, Jong-Hoon Kim,
Beatriz Alvarez, Roberto Gil, Marc Laruelle and Anissa Abi-Dargham
Neuropsychopharmacology (2008) 33, 3111–3125
3 - Antipsychotic-Like Properties of 5-alpha-Reductase Inhibitors
Marco Bortolato, Roberto Frau, Marco Orrù, Youri Bourov, Francesco Marrosu, Giampaolo Mereu, Paola Devoto and Gian L Gessa
Neuropsychopharmacology (2008) 33, 3146–3156
5 - A Meta-Analysis of Head-to-Head Comparisons
of Second-Generation Antipsychotics in the Treatment of Schizophrenia
Stefan Leucht, Katja Komossa, Christine Rummel-Kluge,
Caroline Corves, Heike Hunger, Franziska Schmid, Claudia Asenjo Lobos,
Sandra Schwarz, and John M. Davis
Am J Psychiatry Published November 17, 2008
3! - Correlates
of response to Olanzapine in a North Indian
Schizophrenia sample
Pramod Thomas, Vibhuti Srivastava, Anuradha Singh, Priya Mathur, Vishwajit L. Nimgaonkar, Bernard Lerer, B.K.
Thelma and Smita N. Deshpande
Psychiatry Research. Volume 161, Issue 3, 15 December 2008, Pages 275-283
5 - Safety of
the omega-3 fatty acid, eicosapentaenoic acid (EPA)
in psychiatric patients: Results from a randomized, placebo-controlled trial
Robin Emsley, Dana
J.H Niehaus, Petrus P. Oosthuizen, Liezl Koen, Brynne Ascott-Evans,
Bonginkosi Chiliza, Susan
J. van Rensburg and Retha
M. Smit
Psychiatry Research. Volume 161, Issue 3, 15 December 2008, Pages 284-291
GRATIS 3!
- Orbitofrontal
cortex neurons as a common target for classic and glutamatergic
antipsychotic drugs
Houman Homayoun and Bita Moghaddam
PNAS November 18, 2008vol.
105 no. 46 18041-18046
3! - Glucose Metabolism in Japanese Schizophrenia Patients
Treated With Risperidone or Olanzapine
Norio Yasui-Furukori, Yasushi Sato, Hanako Furukori, Manabu Saito, Taku Nakagami, and Sunao Kaneko
J Clin Psychiatry November 18, 2008: e1-e6
3! - Quetiapine alleviates the cuprizone-induced
white matter pathology in the brain of C57BL/6 mouse
Yanbo Zhang, Haiyun
Xu, Wengao Jiang, Lan Xiao, Bin Yan, Jue He, Yanlin Wang, Xiaoying Bi, Xiaokun Li, Jiming Kong and Xin-Min
Li
Schizophrenia Research. Volume 106, Issues 2-3, December 2008, Pages 182-191
3! - Symptom
remission in first episode patients
Jean Addington and Donald Addington
Schizophrenia Research. Volume 106, Issues 2-3, December 2008, Pages 281-285
2 - Temporal
association of cannabis use with symptoms in individuals at clinical high risk
for psychosis
Cheryl M. Corcoran, David Kimhy,
Arielle Stanford, Shamir Khan, Julie Walsh, Judy Thompson, Scott Schobel, Jill Harkavy-Friedman,
Ray Goetz, Tiziano Colibazzi,
Victoria Cressman and
Dolores Malaspina
Schizophrenia Research. Volume 106, Issues 2-3, December 2008, Pages 286-293
3 - Elevated
rates of substance use disorders in non-psychotic siblings of individuals with
schizophrenia
Matthew J. Smith, Deanna M. Barch, Timothy J. Wolf, Daniel Mamah and John G. Csernansky
Schizophrenia Research. Volume 106, Issues 2-3, December 2008, Pages 294-299
4 - Changes in
non-high-density lipoprotein cholesterol levels and triglyceride/high-density
lipoprotein cholesterol ratios among patients randomized to aripiprazole
versus olanzapine
John W. Newcomer, Jonathan M. Meyer, Ross A.
Baker, James M. Eudicone, Andrei Pikalov,
Estelle Vester-Blokland, Robert D. McQuade, David T. Crandall, William H. Carson, Ronald N.
Marcus and Gilbert L'Italien
Schizophrenia Research. Volume 106, Issues 2-3, December 2008, Pages 300-307
3! - A
cross-sectional evaluation of adiponectin plasma
levels in patients with schizophrenia and schizoaffective disorder
Linda Hanssens, Ruud van Winkel, Martien Wampers, Dominique Van
Eyck, Andre Scheen, Jean-Yves Reginster,
Julien Collette, Joseph Peuskens and Marc De Hert
Schizophrenia Research. Volume 106, Issues 2-3, December 2008, Pages 308-314
3! - Frequency
of abnormal correlation between leptin and the body
mass index during first and second generation antipsychotic drug treatment
Rocio Peña,
David Marquina, Ana Serrano, Yamily
elFakih, Enma Araujo de Baptista, Edgardo Carrizo, Virginia Fernández,
Lenin Valery, Luis Teneud and Trino Baptista
Schizophrenia Research. Volume 106, Issues 2-3, December 2008, Pages 315-319
3! - Clinical
Potential of Minocycline for Schizophrenia
Miyaoka,
Tsuyoshi
CNS & Neurological Disorders - Drug Targets,
Volume 7, Number 4, October 2008 , pp. 376-381(6)
3 - Changes in
weight and weight-related quality of life in a multicentre, randomized trial of
aripiprazole versus standard of care
Ronette L. Kolotkin, Patricia K. Corey-Lisle, Ross D. Crosby, Hong J. Kan and Robert
D. McQuade
European Psychiatry. Volume 23, Issue
8, December 2008, Pages
561-566
3 -
Pharmacological treatment effects on eye movement control
James L. Reilly, Rebekka
Lencer, Jeffrey R. Bishop, Sarah Keedy and John A. Sweeney
Brain
and Cognition. Volume 68, Issue 3, December 2008, Pages 415-435
3 - Modafinil as an Adjunctive
Treatment of Sedation, Negative Symptoms, and Cognition in Schizophrenia: A
Critical Review
Carlos Saavedra-Velez, Anna Yusim, Deepti Anbarasan,
and Jean-Pierre Lindenmayer
J Clin Psychiatry November 18, 2008: e1-e9
3< - Aripiprazole in
Schizophrenia Patients With Comorbid
Obsessive-Compulsive Symptoms: An Open-Label Study of 15 Patients
Ira D. Glick, Michael Poyurovsky, Oxana Ivanova, and Lorrin M. Koran
J Clin Psychiatry November 18, 2008: e1-e4
3 - Risperidone Long-Acting
Injection: A Prospective 3-Year Analysis of Its Use in Clinical Practice
David M. Taylor, Catrin Fischetti,
Anna Sparshatt, Arwel
Thomas, Delia Bishara, and Victoria Cornelius
J Clin Psychiatry November 18, 2008: e1-e
3! - Lower
serum cytokine levels in smokers than nonsmokers with
chronic schizophrenia on long-term treatment with antipsychotics
Xiang Yang Zhang, Lian Yuan Cao,
Cai Song, Gui Ying Wu,
Da Chun Chen, Ling Yan Qi, Fan Wang, Mei Hong Xiu,
Song Chen, Yingyang Zhang, Lin Lu,
Therese A. Kosten and
Thomas R. Kosten
Psychopharmacology. Volume 201, Number 3 / December 2008 : 383-389
3 -
Antipsychotics possessing antidepressive efficacy
increase Golf protein in rat striatum
Hideki Taoka, Takashi Hamamura, Shiro Endo,
Shinji Miyata, Kishio Toma,
Takeshi Ishihara and Shigetoshi Kuroda
Psychopharmacology. Volume 201, Number 2 / December 2008: 229-235
3 - Preclinical
investigations into the antipsychotic potential of the novel histamine H3 receptor
antagonist GSK207040
Eric Southam, Jackie Cilia,
Jane E. Gartlon,
Marie L. Woolley, Laurent P. Lacroix,
Carol A. Jennings, Jane E. Cluderay,
Charlie Reavill, Claire Rourke,
David M. Wilson, Lee A. Dawson, Andrew D. Medhurst and Declan N. C. Jones
Psychopharmacology. Volume 201, Number 4 / enero de 2009: 483-494
4< - A randomised controlled study of risperidone
and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia
or parkinsonism
HY Chan, CJ Chang, SC
Chiang, JJ Chen, CH Chen, HJ Sun, HG Hwu, and MS Lai
J Psychopharmacol. First published on
September 18, 2008
3! - Effects of
haloperidol and risperidone on the expression of heat
shock protein 70 in MK-801-treated rat C6 glioma
cells
Kyungsoo Roh,
Sungwon Roh, Byung-Hwan Yang, Jun-Seok Lee,
Young Gyu Chai, Mi Ran Choi, Yong Chon Park, Dai-Jin Kim, Daeho
Kim, Joonho Choi and Seok Hyeon Ki
5 - A 12-week,
double-blind, placebo-controlled trial of donepezil
adjunctive treatment to risperidone in chronic and
stable schizophrenia
Shahin Akhondzadeh,
Maryam Gerami, Maryam Noroozian, Narges Karamghadiri, Aboulfazl Ghoreishi, Seyed-Hesameddin Abbasi and Sams-Ali
Rezazadeh
3! - An
integrated psychobiological predictive model of emergent psychopathology among
young relatives at risk for schizophrenia
Shaun M. Eack, Konasale M.R. Prasad, Debra M. Montrose, Dhruman D. Goradia, Diana Dworakowski, Jean Miewald and Matcheri
S. Keshavan
3 - Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of
schizophrenia: A double-blind randomized placebo-controlled study
Shahin Akhondzadeh,
Mojgan Malek-Hosseini, Aboulfazl Ghoreishi, Maedeh Raznahan and Shams-Ali Rezazadeh
3! -
Pharmacokinetics of olanzapine in Chinese male
schizophrenic patients with various smoking behaviors
Tzu-Hua Wu, Chih-Chiang Chiu, Winston W. Shen,
Fang-Wei Lin, Li-Hsuan Wang, Hsiang-Yu Chen and Mong-Liang
Lu
3 - Plasma homocysteine levels in young male patients in the
exacerbation and remission phase of schizophrenia
Nataša D. Petronijević,
Nevena V. Radonjić, Maja D. Ivković, Dragan Marinković, Vesna D. Piperski, Bogdan M. Đuričić and Vladimir R. Paunović
3 - Effect of
antipsychotic drugs on brain morphometry.: A randomized controlled one-year follow-up study of
haloperidol, risperidone and olanzapine
Benedicto Crespo-Facorro,
Roberto Roiz-Santiáñez, Rocío
Pérez-Iglesias, José M. Pelayo-Terán,
José M. Rodríguez-Sánchez, Diana Tordesillas-Gutiérrez,
MariLuz Ramírez, Obdulia Martínez, Agustin Gutiérrez, Enrique Marco de Lucas and José L. Vázquez-Barquero
3 - Time course
of the changes in antipsychotic-induced hyperprolactinemia
following the switch to aripiprazole
Mong-Liang Lu, Winston W. Shen and
Chun-Hsin Chen
5 -
Double-Blind, Placebo-Controlled, Multicenter Trial of a Vasopressin V2-Receptor
Antagonist in Patients with Schizophrenia and Hyponatremia
Richard C. Josiassen,
Morris Goldman, Meera Jessani,
Rita A. Shaughnessy, Ala Albazzaz,
Jennifer Lee, John Ouyang, Cesare
Orlandi and Frank Czerwiec
Biological Psychiatry. Volume 64, Issue 12, 15
December 2008, Pages 1097-1100
GRATIS 3
- Muscarinic
Agonists for the Treatment of Cognition in Schizophrenia
Angela K. Sellin, Mujeeb
Shad, and Carol Tamminga
CNS Spectr.
2008;13(11):985-996
GRATIS 3
- Metabolic Syndrome and Atypical
Antipsychotics: A Selective Literature Review
Muthukumar Kannabiran
and Vinod Singh
German J Psychiatry
2008; 11: 111-122
GRATIS 3!
- New Antipsychotic
Agents
Ira D. Glick, and Eric D. Peselow
Primary Psychiatry.
2008;15(12):57-64
| Regresar a RESÚMENES NOVIEMBRE 2008 |